TGFBeta resistant HER2/EBV-CTLs / Baylor Scott & White Research Institute - LARVOL DELTA

HERCREEM-Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Baylor College of Medicine; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Oncology

HERCREEM: Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: Baylor College of Medicine; Active, not recruiting ➔ Completed; Trial completion date: Jun 2030 ➔ Jan 2018

Clinical • Trial completion • Trial completion date